Akero Therapeutics Inc’s recently made public that its President and CEO Cheng Andrew unloaded Company’s shares for reported $1.06 million on Apr 10 ’25. In the deal valued at $35.23 per share,30,000 shares were sold. As a result of this transaction, Cheng Andrew now holds 624,324 shares worth roughly $23.47 million.
Then, Rolph Timothy sold 6,250 shares, generating $224,262 in total proceeds. Upon selling the shares at $35.88, the Chief Scientific Officer now owns 169,721 shares.
Before that, PATRICK D LAMY bought 8,000 shares. Akero Therapeutics Inc shares valued at $293,840 were divested by the Officer at a price of $36.73 per share.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock jump 5.43% to $37.60. Over the last five days, the stock has gained 4.53%. Akero Therapeutics Inc shares have risen nearly 35.15% since the year began. Nevertheless, the stocks have risen 72.16% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $17.86 was recorded on 01/14/25. SMA at 50 days reached $45.38, while 200 days put it at $32.85.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 36.36, which if violated will result in even more drops to 35.12. On the upside, there is a resistance level at 38.34. A further resistance level may holdings at 39.08. The Relative Strength Index (RSI) on the 14-day chart is 43.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.75, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 57.29%. Stochastics %K at 30.74% indicates the stock is a holding.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-03-31, growing by 0.43 million shares to a total of 5.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 5.05 million shares. There was a rise of 7.92%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
